176 related articles for article (PubMed ID: 6091423)
21. Ex vivo effects of ticlopidine on human platelets: inhibition of fibrinogen binding by a mechanism independent of thromboxane formation.
Iovine C; d'Avenia V; Turco S; Mattioli PL; di Minno G
Agents Actions Suppl; 1984; 15():105-7. PubMed ID: 6592941
[No Abstract] [Full Text] [Related]
22. [Evaluation of platelet aggregation in patients treated with ticlopidine].
Sbalzarini G; Carniti E; Fiorini L; Iezzi BG
Clin Ter; 1984 Nov; 111(3):247-50. PubMed ID: 6240365
[No Abstract] [Full Text] [Related]
23. [Platelet aggregation and antiaggregant drugs].
Andriani A; Chiappetta MG; Fabiani M
Recenti Prog Med; 1982 Nov; 73(5):537-42. PubMed ID: 6761807
[No Abstract] [Full Text] [Related]
24. [Pharmacology of anti-platelet agents].
Lecompte T; Kher A; Gaillard JL; Samama M
J Mal Vasc; 1983; 8(1):3-16. PubMed ID: 6302191
[TBL] [Abstract][Full Text] [Related]
25. The effect of oral ticlopidine on arachidonic acid products in human platelets.
Bruno JJ; Chang LF; McSpadden MM; Yang D
Agents Actions Suppl; 1984; 15():76-87. PubMed ID: 6435408
[No Abstract] [Full Text] [Related]
26. [Medical therapy of chronic obstructive arteriopathy of the lower extremities. A controlled clinical study of suloctidil versus xanthinol].
Spinella G; Majorana M
Clin Ter; 1983 Mar; 104(5):375-81. PubMed ID: 6303677
[No Abstract] [Full Text] [Related]
27. Ticlopidine in the secondary prevention of early diabetes-related microangiopathy: protocol of a multicenter therapeutic study (TIMAD study).
Mirouze J
Agents Actions Suppl; 1984; 15():230-58. PubMed ID: 6385649
[No Abstract] [Full Text] [Related]
28. [The antiaggregation effect of ticlopidine on blood platelets preliminary results and prospectives for studies in various diseases].
Andriani A; Chiappetta MG; Fabiani M; Mosiello G; Beni A
Clin Ter; 1983 Feb; 104(3):219-22. PubMed ID: 6345050
[No Abstract] [Full Text] [Related]
29. Platelet function during long-term treatment with ketanserin of claudicating patients with peripheral atherosclerosis. A multi-center, double-blind, placebo-controlled trial. The PACK Trial Group.
Thromb Res; 1989 Jul; 55(1):13-23. PubMed ID: 2528841
[TBL] [Abstract][Full Text] [Related]
30. [Aftercare of heart infarct patients to reduce the risk of a subsequent infarction].
Offerhaus L
Ned Tijdschr Geneeskd; 1983 Apr; 127(16):673-9. PubMed ID: 6134240
[No Abstract] [Full Text] [Related]
31. [Effect of ticlopidine on peripheral obliterating arteriopathy].
Stiegler H; Hess H; Mietaschk A; Trampisch HJ; Ingrisch H
Dtsch Med Wochenschr; 1984 Aug; 109(33):1240-3. PubMed ID: 6381015
[TBL] [Abstract][Full Text] [Related]
32. Platelet survival, atherosclerotic intermittent claudication and ticlopidine.
Hawker RJ; Aukland A
Atherosclerosis; 1984 Feb; 50(2):147-58. PubMed ID: 6712768
[TBL] [Abstract][Full Text] [Related]
33. Effects of ticlopidine on platelet function and blood coagulation.
Violi F; Alessandri C; Frattaroli S; Ghiselli A; Balsano F
Thromb Haemost; 1982 Oct; 48(2):166-8. PubMed ID: 6217577
[TBL] [Abstract][Full Text] [Related]
34. Effects of long-term ticlopidine treatment on platelet function and its tolerability in cerebrovascular disease.
Carrieri P; Orefice G; Fioretti A; Indaco A; Carfagna S
J Int Med Res; 1984; 12(5):286-91. PubMed ID: 6500168
[TBL] [Abstract][Full Text] [Related]
35. [Use of nitrendipine in treating patients with obliterative atherosclerosis of arteries in the lower extremities].
Grodzińska L; Kostka-Trabka E; Basista M; Bieroń K; Sławiński M; Telesz E
Pol Tyg Lek; 1991 Aug 5-19; 46(32-34):598-600. PubMed ID: 1669121
[TBL] [Abstract][Full Text] [Related]
36. [Comparative action of different platelet anti-aggregants in the postoperative period].
Lapeyrère X; Gruyer P; Guyot L; Barbe G; Saint-Paul B
Cah Anesthesiol; 1984 Mar; 32(2):123-5. PubMed ID: 6529644
[No Abstract] [Full Text] [Related]
37. Intradialytic and postdialytic platelet activation, increased platelet phosphatidylserine exposure and ultrastructural changes in platelets in children with chronic uremia.
Elshamaa MF; Elghoroury EA; Helmy A
Blood Coagul Fibrinolysis; 2009 Jun; 20(4):230-9. PubMed ID: 19521197
[TBL] [Abstract][Full Text] [Related]
38. The thrombogenicity of Dacron arterial grafts and its modification by platelet inhibitory drugs.
Kester RC
Ann R Coll Surg Engl; 1984 Jul; 66(4):241-6. PubMed ID: 6234841
[TBL] [Abstract][Full Text] [Related]
39. Antiplatelet drugs and thrombosis prevention: ticlopidine in perspective.
de Gaetano G; Bertelé V
Arq Bras Cardiol; 1983 Dec; 41(6):425-7. PubMed ID: 6678584
[No Abstract] [Full Text] [Related]
40. Platelet factors predisposing to arterial thrombosis.
Harker LA; Hanson SR
Baillieres Clin Haematol; 1994 Sep; 7(3):499-522. PubMed ID: 7841598
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
